| Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements MC Haffner, MJ Aryee, A Toubaji, DM Esopi, R Albadine, B Gurel, ... Nature genetics 42 (8), 668-675, 2010 | 688 | 2010 |
| Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ... The Lancet Oncology 21 (1), 162-174, 2020 | 630 | 2020 |
| Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis B Gurel, T Iwata, CM Koh, RB Jenkins, F Lan, C Van Dang, JL Hicks, ... Modern Pathology 21 (9), 1156-1167, 2008 | 523 | 2008 |
| PTEN protein loss by immunostaining: Analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients TL Lotan, B Gurel, S Sutcliffe, D Esopi, W Liu, J Xu, JL Hicks, BH Park, ... Clinical Cancer Research 17 (20), 6563-6573, 2011 | 404 | 2011 |
| Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer A Paschalis, B Sheehan, R Riisnaes, DN Rodrigues, B Gurel, C Bertan, ... European Urology, 2019 | 397 | 2019 |
| DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity S Yegnasubramanian, MC Haffner, Y Zhang, B Gurel, TC Cornish, Z Wu, ... Cancer research 68 (21), 8954-8967, 2008 | 353 | 2008 |
| NKX3. 1 as a marker of prostatic origin in metastatic tumors B Gurel, TZ Ali, EA Montgomery, S Begum, J Hicks, M Goggins, ... The American journal of surgical pathology 34 (8), 1097-1105, 2010 | 344 | 2010 |
| Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial B Gurel, MS Lucia, IM Thompson, PJ Goodman, CM Tangen, AR Kristal, ... Cancer Epidemiology Biomarkers & Prevention 23 (5), 847-856, 2014 | 298 | 2014 |
| Genomics of lethal prostate cancer at diagnosis and castration resistance J Mateo, G Seed, C Bertan, P Rescigno, D Dolling, I Figueiredo, ... The Journal of clinical investigation 130 (4), 1743-1751, 2020 | 268 | 2020 |
| Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy SR Denmeade, AM Mhaka, DM Rosen, WN Brennen, S Dalrymple, I Dach, ... Science translational medicine 4 (140), 140ra86-140ra86, 2012 | 258 | 2012 |
| Targeting the p300/CBP axis in lethal prostate cancer J Welti, A Sharp, N Brooks, W Yuan, C McNair, SN Chand, A Pal, ... Cancer Discovery 11 (5), 1118-1137, 2021 | 186 | 2021 |
| Prostate carcinogenesis: inflammatory storms JS de Bono, C Guo, B Gurel, AM De Marzo, KS Sfanos, RS Mani, J Gil, ... Nature Reviews Cancer 20 (8), 455-469, 2020 | 173 | 2020 |
| Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene CM Koh, B Gurel, S Sutcliffe, MJ Aryee, D Schultz, T Iwata, M Uemura, ... The American journal of pathology 178 (4), 1824-1834, 2011 | 144 | 2011 |
| Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats S Atasayar, H Gürer-Orhan, H Orhan, B Gürel, G Girgin, H Özgüneş Experimental and Toxicologic Pathology 61 (1), 23-32, 2009 | 129 | 2009 |
| An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy ES Antonarakis, D Keizman, Z Zhang, B Gurel, TL Lotan, JL Hicks, ... Cancer 118 (24), 6063-6071, 2012 | 123 | 2012 |
| Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial S Carreira, N Porta, S Arce-Gallego, G Seed, A Llop-Guevara, D Bianchini, ... Cancer discovery 11 (11), 2812-2827, 2021 | 122 | 2021 |
| Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization MC Haffner, C Weier, MM Xu, A Vaghasia, B Gürel, B Gümüşkaya, ... The Journal of pathology 238 (1), 31-41, 2016 | 112 | 2016 |
| Loss of Nkx3. 1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia M Khalili, LN Mutton, B Gurel, JL Hicks, AM De Marzo, CJ Bieberich The American journal of pathology 176 (5), 2259-2268, 2010 | 101 | 2010 |
| Advanced prostate cancer with ATM loss: PARP and ATR inhibitors A Neeb, N Herranz, S Arce-Gallego, S Miranda, L Buroni, W Yuan, A Athie, ... European Urology 79 (2), 200-211, 2021 | 96 | 2021 |
| Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. B Gurel, T Iwata, CM Koh, S Yegnasubramanian, WG Nelson, ... Advances in anatomic pathology 15 (6), 319-331, 2008 | 94 | 2008 |
Angelo M. De Marzo M.D., Ph.D.Professor of Pathology, Urology and Oncology, The Johns Hopkins University School of MedicineVerified email at jhmi.edu